Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Clinical and Translational Science
|
July 24, 2020
Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium
Bianca D van Groen, Venkatesh Pilla Reddy, Justine Badée, et al.
Science Translational Medicine
|
August 19, 2021
ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156
Balakrishna Koneru, Ahsan Farooqi, Thinh H Nguyen, et al.
Molecular Pharmaceutics
|
June 15, 2026
Quantifying Transporter Activity: An Absolute Scaling Approach Using Digoxin
Maïlys De Sousa Mendes, Venkatesh Pilla-Reddy, Hong Shen, et al.
The Journal of Infectious Diseases
|
January 23, 2023
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
Pablo Forte-Soto, Muna Albayaty, Dennis Brooks, et al.
Clinical Pharmacology and Therapeutics
|
July 7, 2022
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection
Rachel A Bender Ignacio, David A Wohl, Rosalin Arends, et al.
Infectious Diseases and Therapy
|
September 26, 2023
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
F D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
Clinical Pharmacology and Therapeutics
|
October 20, 2019
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations
Kunal S Taskar, Venkatesh Pilla Reddy, Howard Burt, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 27, 2025
Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase
Nicola Colclough, Alexandra L Orton, Scott Martin, et al.
Neuro-Oncology
|
October 30, 2020
Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study
Aurelija Jucaite, Per Stenkrona, Zsolt Cselényi, et al.
Clinical Pharmacology and Therapeutics
|
October 18, 2024
Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective
Micaela B Reddy, Tamara D Cabalu, Loeckie de Zwart, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Clinical and Translational Science
|
July 24, 2020
Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium
Bianca D van Groen, Venkatesh Pilla Reddy, Justine Badée, et al.
Science Translational Medicine
|
August 19, 2021
ALT neuroblastoma chemoresistance due to telomere dysfunction-induced ATM activation is reversible with ATM inhibitor AZD0156
Balakrishna Koneru, Ahsan Farooqi, Thinh H Nguyen, et al.
Molecular Pharmaceutics
|
June 15, 2026
Quantifying Transporter Activity: An Absolute Scaling Approach Using Digoxin
Maïlys De Sousa Mendes, Venkatesh Pilla-Reddy, Hong Shen, et al.
The Journal of Infectious Diseases
|
January 23, 2023
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
Pablo Forte-Soto, Muna Albayaty, Dennis Brooks, et al.
Clinical Pharmacology and Therapeutics
|
July 7, 2022
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection
Rachel A Bender Ignacio, David A Wohl, Rosalin Arends, et al.
Infectious Diseases and Therapy
|
September 26, 2023
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial
F D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
Clinical Pharmacology and Therapeutics
|
October 20, 2019
Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations
Kunal S Taskar, Venkatesh Pilla Reddy, Howard Burt, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 27, 2025
Achieving human brain exposure with the oral ataxia-telangiectasia mutated kinase inhibitor AZD1390, a substrate of aldehyde oxidase
Nicola Colclough, Alexandra L Orton, Scott Martin, et al.
Neuro-Oncology
|
October 30, 2020
Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study
Aurelija Jucaite, Per Stenkrona, Zsolt Cselényi, et al.
Clinical Pharmacology and Therapeutics
|
October 18, 2024
Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective
Micaela B Reddy, Tamara D Cabalu, Loeckie de Zwart, et al.
Page
of 6